57279-49-9

Upstream product

• 93-58-3 benzoic acid methyl ester 
• 6964-21-2 thiophen-3-yl-acetic acid 
• 872-31-1 3-Bromothiophene 
• 98-86-2 acetophenone 
• 108-86-1 bromobenzene 
• 654682-77-6 N-methoxy-N-methyl-2-(thiophen-3-yl)acetamide 
• 100-58-3 phenylmagnesium bromide 
• 100-59-4 phenylmagnesium chloride 

Downstream Products

• 1356060-17-7 2-hydroxy-4-(2-oxo-6-phenyl-5-(thiophen-3-yl)-1,2,3,4-tetrahydropyridin-4-yl)benzoic acid 
• 1224397-03-8 1-phenyl-2-(thiophen-3-yl)ethanone-oxime 
• 1283117-04-3 (R)-4-(3-ethoxy-4-hydroxy-5-nitrophenyl)-6-phenyl-5-(thiophen-3-yl)-3,4-dihydropyrimidin-2(1H)-one 
• 1283117-03-2 (S)-4-(3-ethoxy-4-hydroxy-5-nitrophenyl)-6-phenyl-5-(thiophen-3-yl)-3,4-dihydropyrimidin-2(1H)-one 
• 1283118-32-0 3-ethoxy-2-hydroxy-5-(2-oxo-6-phenyl-5-(thiophen-3-yl)-1,2,3,4-tetrahydropyrimidin-4-yl)benzonitrile 
• 1283117-02-1 4-(3-ethoxy-4-hydroxy-5-nitrophenyl)-6-phenyl-5-(thiophen-3-yl)-3,4-dihydropyrimidin-2(1H)-one 

Relevant academic research and scientific papers

Rearrangements of furan-, thiophene- and N-boc-pyrrole-derived donor-acceptor cyclopropanes: Scope and limitations

Rearrangements of furan-, thiophene- and N-Boc-pyrrole-derived donor-acceptor cyclopropanes initiated by Bronsted acids were investigated. Throughout the study, ketones or aldehydes were utilized as accepting moieties and oxygen, sulfur and Boc-protected nitrogen were used as the donor atoms. Whether a ring-enlargement and thus an annelation of a five-membered ring, or a ring-opening of the three-membered ring followed by rearomatization to the parent heterocycles takes place strongly depends on the substitution pattern of the cyclopropane. Commonly, more substituted substrates led to annelation whereas less substituted substrates tend to undergo rearomatization. In general, good yields were obtained for starting materials with oxygen and nitrogen donors, whereas the reactions with sulfur as donor gave only poor yields. Bronsted acid catalyzed ring-enlargement and ring-opening reactions of donor-acceptor cyclopropanes with ketones as accepting unit and oxygen, sulfur and nitrogen as electron-donating moiety have been investigated. The mode of intramolecular rearrangement of the carbonyl-substituted cyclopropanes depends on subtle differences in the substitution pattern of the cyclopropane. Copyright

The organocatalytic enantiodivergent fluorination of β-ketodiaryl-phosphine oxides for the construction of carbon-fluorine quaternary stereocenters

Commercially available cinchona alkaloids that can catalyze the enantiodivergent fluorination of β-ketodiarylphosphine oxides were developed to construct carbon-fluorine quaternary stereocenters. This protocol features a wide scope of substrates and excellent enantioselectivities, and it is scalable.

Palladium-Catalyzed Direct α-C(sp3) Heteroarylation of Ketones under Microwave Irradiation

Heteroaryl compounds are valuable building blocks in medicinal chemistry and chemical industry. A palladium-catalyzed direct α-C(sp3) heteroarylation of ketones under microwave irradiation is developed and reported in this study. Under optimized condition

NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS

The present invention is directed to novel dihydropyridin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors and/or Neurokinin-3 (NK3) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators

Substituted tetrahydrothienopyridines corresponding to formula (1) in which A1 through A3 and R1 through R12 have defined meanings, pharmaceutical compositions comprising such compounds, a process for preparing such compounds and the use of such compounds in treatment or inhibition of conditions mediated by the KCNQ 2/3 K+ channel, e.g., pain.